Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04406623 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | PHASE1 | COMPLETED | 27 | — | — | Jun 29, 2020 | Feb 2, 2023 | Jan 30, 2025 | 6 | United States |
Number of participants with treatment emergent adverse events
Number of participants with dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| SL-172154 | EXPERIMENTAL | Intravenous administration |
| Name | Type | Description |
|---|---|---|
| SL-172154 | DRUG | The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply: 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Subject must have a his...